O. Gheith, N. Othman, N. Nampoory, M. A. Halimb, and T. Al-otaibi, Diabetic kidney disease: difference in the prevalence and risk factors worldwide, Journal of The Egyptian Society of Nephrology and Transplantation, vol.16, issue.3, p.65, 2016.

J. Dean, ORGANISING CARE FOR PEOPLE WITH DIABETES AND RENAL DISEASE, Journal of Renal Care, vol.38, pp.23-29, 2012.

L. Li, S. Jick, C. Gopalakrishnan, U. Heide-jørgensen, H. Nørrelund et al., Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK, Diabetic Medicine, vol.34, issue.4, pp.485-489, 2016.

L. Li, S. Jick, C. Gopalakrishnan, U. Heide-jørgensen, H. Nørrelund et al., Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK, Diabetic Medicine, vol.34, issue.4, pp.485-489, 2016.

S. E. Inzucchi, K. J. Lipska, H. Mayo, C. J. Bailey, and D. K. Mcguire, Metformin in Patients With Type 2 Diabetes and Kidney Disease, JAMA, vol.312, issue.24, p.2668, 2014.

M. Alsahli and J. E. Gerich, Hypoglycemia in Patients with Diabetes and Renal Disease, Journal of Clinical Medicine, vol.4, issue.5, pp.948-964, 2015.

F. Kajbaf, P. Arnouts, M. De-broe, and J. D. Lalau, Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world, Pharmacoepidemiology and Drug Safety, vol.22, issue.10, pp.1027-1035, 2013.

. &na;, US FDA 2009 drug safety warnings analysed, Reactions Weekly, vol.&NA;, issue.1388, p.4, 2012.

J. Shin, A. Chang, J. Coresh, L. A. Inker, E. Selvin et al., Abstract 037: The U.S. Food and Drug Administration?s Metformin Label Change Reduces Racial Disparity in Metformin Use by Increasing Its Use Among Black Patients With Type 2 Diabetes and Moderately Impaired Kidney Function, Circulation, vol.139, issue.Suppl_1, 2019.

M. J. Davies, D. A. D?alessio, J. A. Fradkin, W. N. Kernan, C. N. Mathieu et al., Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, vol.61, issue.12, pp.2461-2498, 2018.

M. J. Davies, D. A. D?alessio, J. Fradkin, W. N. Kernan, C. Mathieu et al., Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, vol.61, issue.12, pp.2461-2498, 2018.

, Up Front, Diabetologia, vol.61, issue.9, pp.1893-1894, 2018.

A. J. Bergman, J. Cote, B. Yi, T. Marbury, S. K. Swan et al., Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Diabetes Care, vol.30, issue.7, pp.1862-1864, 2007.

Y. L. He, Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin, Clinical Pharmacokinetics, vol.51, issue.3, pp.147-162, 2012.

P. A. Bittle, The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease, The Nurse Practitioner, vol.42, issue.6, pp.31-38, 2017.

A. Penfornis, J. F. Blickle, B. Fiquet, S. Quere, and S. Dejager, How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag, vol.10, pp.341-52, 2014.

L. Becquemont, B. Bauduceau, L. Benattar-zibi, A. , A. Berrut et al.,

L. Becquemont, B. Bauduceau, L. Benattar-zibi, A. Al-salameh, G. Berrut et al., Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Non-Institutionalized Elderly Patients, Basic & Clinical Pharmacology & Toxicology, vol.118, issue.6, pp.468-473, 2015.

A. Douros, N. Ebert, O. Jakob, P. O. Martus, R. Kreutz et al., Estimating kidney function and use of oral antidiabetic drugs in elderly, Fundamental & Clinical Pharmacology, vol.29, issue.3, pp.321-328, 2015.

A. Solini, G. Penno, E. Bonora, C. Fondelli, E. Orsi et al., Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study, Journal of the American Geriatrics Society, vol.61, issue.8, pp.1253-1261, 2013.

B. Detournay, D. Simon, P. J. Guillausseau, D. Joly, B. Verges et al., Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes, Diabetes & Metabolism, vol.38, issue.2, pp.102-112, 2012.

C. Breuker, V. Macioce, T. Mura, A. Castet-nicolas, Y. Audurier et al., Medication Errors at Hospital Admission and Discharge, Journal of Patient Safety, vol.Publish Ahead of Print, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753808

P. Darmon, B. Bauduceau, L. Bordier, J. Bringer, G. Chabrier et al., Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l?hyperglycémie du patient diabétique de type 2, Médecine des Maladies Métaboliques, vol.11, issue.6, pp.577-593, 2017.

T. Min, G. I. Davies, S. Rice, J. Chess, and J. W. Stephens, Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol.12, issue.2, pp.123-127, 2018.

C. F. Christiansen, V. Ehrenstein, U. Heide-jørgensen, S. Skovbo, H. Nørrelund et al., Metformin initiation and renal impairment: a cohort study in Denmark and the UK, BMJ Open, vol.5, issue.9, p.e008531, 2015.

G. F. Assogba, C. Couchoud, C. Roudier, C. Pornet, S. Fosse et al., Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007), Diabetes & Metabolism, vol.38, issue.6, pp.558-566, 2012.

A. P. Mcgovern, B. Rusholme, S. Jones, J. N. Van-vlymen, H. Liyanage et al., Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study, BMC Nephrology, vol.14, issue.1, 2013.

A. P. Mcgovern, B. Rusholme, S. Jones, J. N. Van-vlymen, H. Liyanage et al., Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study, BMC Nephrology, vol.14, issue.1, 2013.

W. R. Lu, J. Defilippi, and A. Braun, Unleash Metformin, Annals of Pharmacotherapy, vol.47, issue.11, pp.1488-1497, 2013.

J. D. Lalau, F. Kajbaf, Y. Bennis, A. S. Hurtel-lemaire, F. Belpaire et al., Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4, Diabetes Care, vol.41, issue.3, pp.547-553, 2018.

J. Van-dalem, M. C. Brouwers, C. D. Stehouwer, A. Krings, H. G. Leufkens et al., Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study, BMJ, vol.354, p.i3625, 2016.

. Diabète, ROA Fact Sheets, 2020, 2020.

. Qu'est-ce-que-le-diabète,

D. Sur,

P. Jouannet, Le don de sperme, accès aux origines et paternité, La maîtrise de la vie, p.145, 2012.

, Brève : Diabète de type 2 juvénile pire que diabète de type 1, Revue Francophone des Laboratoires, vol.2014, issue.461, p.16, 2014.

P. Le-coz, Quel rôle pour le Comité consultatif national d?éthique au sein de la cité ?, Éthique & Santé, vol.11, issue.2, pp.105-110, 2014.

D. Sur,

S. Fuentes, S. Fosse-edorh, P. Bernillon, C. Bonaldi, and E. Cosson, 1618-P: Time Trends of Diabetes Prevalence and Incidence in France: A Nationwide Study, Diabetes, vol.68, issue.Supplement 1, pp.1618-P, 2019.

D. Sur, 1.12 Prévalence et incidence du diabète
URL : https://hal.archives-ouvertes.fr/hal-00694954

, Le commerce mondial en 2011

D. Sur,

C. Piffaretti, Incidence du diabète de type 1 chez l'enfant en France en 2013-2015. A partir du systême national des données de santé (SNDS) (internet) (cité, vol.10

D. Sur, http://ljournal.ru/wp-content/uploads/2017/03/a-2017-023.pdf, 2017.

S. Niinistö, H. Takkinen, L. Uusitalo, J. Rautanen, N. Vainio et al., Maternal intake of fatty acids and their food sources during lactation and the risk of preclinical and clinical type 1 diabetes in the offspring, Acta Diabetologica, vol.52, issue.4, pp.763-772, 2015.

H. Beyan, L. Wen, and R. D. Leslie, Guts, Germs, and Meals: The Origin of Type 1 Diabetes, Current Diabetes Reports, vol.12, issue.5, pp.456-462, 2012.

W. Yeung, W. D. Rawlinson, and M. E. Craig, Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies, BMJ, vol.342, issue.feb03 1, pp.d35-d35, 2011.

G. J. Kahaly and M. P. Hansen, Type 1 diabetes associated autoimmunity, Autoimmunity Reviews, vol.15, issue.7, pp.644-648, 2016.

E. Scherer-philipp, J. A. Hill, and . Obesity, Diabetes, and Cardiovascular Diseases, Circulation Research. 27 mai, vol.118, issue.11, pp.1703-1708, 2016.

W. Xu, Z. Xu, J. Jia, Y. Xie, H. Wang et al., Detection of Prediabetes and Undiagnosed Type 2 Diabetes: A Large Population-Based Study, Canadian Journal of Diabetes, vol.36, issue.3, pp.108-113, 2012.

P. J. Boyle, Diabetes Mellitus and Macrovascular Disease: Mechanisms and Mediators, The American Journal of Medicine, vol.120, issue.9, pp.S12-S17, 2007.

P. M. Seferovi?, M. C. Petrie, G. S. Filippatos, S. D. Anker, G. Rosano et al., Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology, European Journal of Heart Failure, vol.20, issue.5, pp.853-72, 2018.

S. P. Laing, A. J. Swerdlow, S. D. Slater, A. C. Burden, A. Morris et al., Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia, vol.46, issue.6, pp.760-765, 2003.

. Spf and . Le-poids-du-diabète-en-france-en, LE POIDS DÉMOGRAPHIQUE DES FEMMES SEULES EN FRANCE (Deuxième moitié du XIXe siècle), 1981, pp.215-228, 1981.

D. Sur,

H. Tellier, S. Colson, and S. Gentile, Améliorer la prise en charge de l?enfant atteint de diabète de type 1 et celle de sa famille : quel rôle pour l?infirmière de pratique avancée, coordinatrice de parcours complexe de soins ? Une étude qualitative et exploratoire, Recherche en soins infirmiers, vol.N° 136, issue.1, p.80, 2019.

H. Autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

P. Zhang, J. Lu, Y. Jing, S. Tang, D. Zhu et al., Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis, Annals of Medicine, vol.49, issue.2, pp.106-116, 2016.

P. A. Lazzarini, S. E. Hurn, M. E. Fernando, S. D. Jen, S. S. Kuys et al., Prevalence of foot disease and risk factors in general inpatient populations: a systematic review and meta-analysis, BMJ Open, vol.5, issue.11, p.e008544, 2015.

N. Singh, D. G. Armstrong, and B. A. Lipsky, Preventing Foot Ulcers in Patients With Diabetes, JAMA, vol.293, issue.2, p.217, 2005.

J. L. Gross, M. J. De-azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori et al., Diabetic Nephropathy: Diagnosis, Prevention, and Treatment, Diabetes Care, vol.28, issue.1, pp.164-176, 2004.

N. Chaturvedi, S. Bandinelli, R. Mangili, G. Penno, R. E. Rottiers et al., Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold, Kidney International, vol.60, issue.1, pp.219-227, 2001.

J. Halimi, S. Hadjadj, V. Aboyans, F. Allaert, J. Artigou et al., Microalbuminuria and urinary albumin excretion: French clinical practice guidelines, Diabetes & Metabolism, vol.33, issue.4, pp.303-309, 2007.

P. Darmon, B. Bauduceau, L. Bordier, B. Charbonnel, E. Cosson et al., Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l?hyperglycémie du patient diabétique de type 2 ? 2019, Médecine des Maladies Métaboliques, vol.13, issue.8, pp.711-732, 2019.

P. Darmon, B. Bauduceau, L. Bordier, J. Bringer, G. Chabrier et al., Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l?hyperglycémie du patient diabétique de type 2, Médecine des Maladies Métaboliques, vol.11, issue.6, pp.577-593, 2017.

O. Phan, Y. E. Housseini, M. Burnier, and B. Vogt, Rein et tabac : revue de la littérature et mise au point, Néphrologie & Thérapeutique, vol.9, issue.2, pp.67-72, 2013.

D. Sur, LAS VEGAS SANDS CORP., a Nevada corporation, Plaintiff, v. UKNOWN REGISTRANTS OF www.wn0000.com, www.wn1111.com, www.wn2222.com, www.wn3333.com, www.wn4444.com, www.wn5555.com, www.wn6666.com, www.wn7777.com, www.wn8888.com, www.wn9999.com, www.112211.com, www.4456888.com, www.4489888.com, www.001148.com, and www.2289888.com, Defendants., Gaming Law Review and Economics, vol.20, issue.10, pp.859-868, 2016.

C. Couchoud, A. Fagot-campagna, and B. Stengel, Fréquence de l?insuffisance rénale chronique terminale (traitée) chez les personnes diabétiques (traitées pharmacologiquement), Revue d'Épidémiologie et de Santé Publique, vol.56, issue.5, p.303, 2008.

F. Bonnet, E. Gauthier, H. Gin, S. Hadjadj, J. Halimi et al., Expert consensus on management of diabetic patients with impairment of renal function, Diabetes & Metabolism, vol.37, pp.S1-S25, 2011.

G. F. Assogba, C. Couchoud, C. Roudier, C. Pornet, S. Fosse et al., Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007), Diabetes & Metabolism, vol.38, issue.6, pp.558-566, 2012.

L. A. Stevens, J. Coresh, T. Greene, and A. S. Levey, Assessing Kidney Function ? Measured and Estimated Glomerular Filtration Rate, New England Journal of Medicine, vol.354, issue.23, pp.2473-2483, 2006.

A. S. Levey, J. Coresh, T. Greene, L. A. Stevens, Y. (. Zhang et al., Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate, Annals of Internal Medicine, vol.145, issue.4, p.247, 2006.

M. Froissart, J. Rossert, C. Jacquot, M. Paillard, and P. Houillier, Predictive Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Estimating Renal Function, Journal of the American Society of Nephrology, vol.16, issue.3, pp.763-773, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00149221

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. (. Zhang, A. F. Castro et al., A New Equation to Estimate Glomerular Filtration Rate, Annals of Internal Medicine, vol.150, issue.9, p.604, 2009.

H. A. De-santé, Évaluation du débit de filtration glomérulaire et du dosage de la créatininémie dans le diagnostic de la maladie rénale chronique chez l?adulte, Bio tribune magazine, vol.41, issue.1, pp.6-9, 2011.

D. Sur, Eau disponible pour l'utilisation, 2017.

A. Schwandt, M. Denkinger, P. Fasching, M. Pfeifer, C. Wagner et al., Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes, Journal of Diabetes and its Complications, vol.31, issue.9, pp.1376-1383, 2017.

K. Matsushita, B. K. Mahmoodi, M. Woodward, J. R. Emberson, T. H. Jafar et al., Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate, JAMA, vol.307, issue.18, pp.1941-51, 2012.

I. Drion, H. Joosten, L. Santing, S. J. Logtenberg, K. H. Groenier et al., The Cockcroft-Gault: A Better Predictor of Renal Function in an Overweight and Obese Diabetic Population, Obesity Facts, vol.4, issue.5, pp.393-399, 2011.

E. G. Camargo, A. A. Soares, A. B. Detanico, L. S. Weinert, F. V. Veronese et al., The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is less accurate in patients with Type 2 diabetes when compared with healthy individuals, Diabetic Medicine, vol.28, issue.1, pp.90-95, 2010.

R. J. Macisaac, E. I. Ekinci, E. Premaratne, Z. X. Lu, J. Seah et al., The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function, BMC Nephrology, vol.16, issue.1, p.198, 2015.

N. Rognant, S. Lemoine, M. Laville, A. Hadj-aissa, and L. Dubourg, Performance of the Chronic Kidney Disease Epidemiology Collaboration Equation to Estimate Glomerular Filtration Rate in Diabetic Patients, Diabetes Care, vol.34, issue.6, pp.1320-1322, 2011.

G. Targher, G. Zoppini, W. Mantovani, M. Chonchol, C. Negri et al., Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes, Diabetes Care, vol.35, issue.11, pp.2347-2353, 2012.

F. Iliadis, T. Didangelos, A. Ntemka, A. Makedou, E. Moralidis et al., Glomerular filtration rate estimation in patients with type 2 diabetes: creatinine- or cystatin C-based equations?, Diabetologia, vol.54, issue.12, pp.2987-2994, 2011.

S. Zoungas, H. Arima, H. C. Gerstein, R. R. Holman, M. Woodward et al., Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials, The Lancet Diabetes & Endocrinology, vol.5, issue.6, pp.431-437, 2017.

B. Fullerton, K. Jeitler, M. Seitz, K. Horvath, A. Berghold et al., Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus, Cochrane Database of Systematic Reviews, issue.2, p.9122, 2014.

, The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, New England Journal of Medicine, vol.329, issue.14, pp.977-986, 1993.

M. J. Davies, D. A. D?alessio, J. A. Fradkin, W. N. Kernan, C. N. Mathieu et al., Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, vol.61, issue.12, pp.2461-2498, 2018.

L. Becquemont, B. Bauduceau, L. Benattar-zibi, A. Al-salameh, G. Berrut et al., Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Non-Institutionalized Elderly Patients, Basic & Clinical Pharmacology & Toxicology, vol.118, issue.6, pp.468-473, 2015.

I. Ruiz-tamayo, J. Franch-nadal, M. Mata-cases, D. Mauricio, X. D. Cos et al., Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?, Journal of Diabetes Research, vol.2016, pp.1-9, 2016.

C. Muller, Y. Dimitrov, O. Imhoff, S. Richter, J. Ott et al., Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?, Journal of Diabetes and its Complications, vol.30, issue.4, pp.675-680, 2016.

S. P. Marso, G. H. Daniels, K. Brown-frandsen, P. Kristensen, J. F. Mann et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.311-322, 2016.

H. C. Gerstein, H. M. Colhoun, G. R. Dagenais, R. Diaz, M. Lakshmanan et al., Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, Lancet, vol.13, pp.131-139, 2019.

B. Bauduceau, L. Bordier, J. Bringer, G. Chabrier, B. Charbonnel et al., Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2, Médecine des Maladies Métaboliques, vol.13, issue.2, pp.195-209, 2019.

B. Neal, V. Perkovic, K. W. Mahaffey, D. De-zeeuw, G. Fulcher et al., Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes, New England Journal of Medicine, vol.377, issue.7, pp.644-657, 2017.

C. Wanner, S. E. Inzucchi, J. M. Lachin, D. Fitchett, M. Von-eynatten et al., Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.323-334, 2016.

O. Mosenzon, S. D. Wiviott, A. Cahn, A. Rozenberg, I. Yanuv et al., Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE?TIMI 58 randomised trial, The Lancet Diabetes & Endocrinology, vol.7, issue.8, pp.606-617, 2019.

S. Chen, Y. Lee, V. Alas, M. Greene, and D. Brixner, Outcomes Associated with Nonconcordance to National Kidney Foundation Guideline Recommendations for Oral Antidiabetic Drug Treatments in Patients with Concomitant Type 2 Diabetes and Chronic Kidney Disease, Endocrine Practice, vol.20, issue.3, pp.221-231, 2014.

D. Kirpichnikov, S. I. Mcfarlane, and J. R. Sowers, Metformin: An Update, Annals of Internal Medicine, vol.137, issue.1, p.25, 2002.

T. Van-staa, L. Abenhaim, and J. Monette, Rates of hypoglycemia in users of sulfonylureas, Journal of Clinical Epidemiology, vol.50, issue.6, pp.735-741, 1997.

W. Rathmann, K. Kostev, J. B. Gruenberger, M. Dworak, G. Bader et al., Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis, Diabetes, Obesity and Metabolism, vol.15, issue.1, pp.55-61, 2012.

C. Breuker, F. Clement, T. Mura, V. Macioce, A. Castet-nicolas et al., Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors, International Journal of Cardiology, vol.268, pp.195-199, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01849461

S. H. Simpson, S. R. Majumdar, R. T. Tsuyuki, R. Z. Lewanczuk, R. Spooner et al., Effect of Adding Pharmacists to Primary Care Teams on Blood Pressure Control in Patients With Type 2 Diabetes: A randomized controlled trial, Diabetes Care, vol.34, issue.1, pp.20-26, 2010.

L. L. Leape, D. J. Cullen, M. D. Clapp, E. Burdick, H. J. Demonaco et al., Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care Unit, JAMA, vol.282, issue.3, p.267, 1999.

B. Allenet, M. Juste, C. Mouchoux, R. Collomp, X. Pourrat et al., De la dispensation au plan pharmaceutique personnalisé : vers un modèle intégratif de pharmacie clinique, Le Pharmacien Hospitalier et Clinicien, vol.54, issue.1, pp.56-63, 2019.

, Actualités internationales, Le Pharmacien Hospitalier et Clinicien, vol.54, issue.1, pp.64-71, 2019.

S. Doerper, S. Morice, D. Piney, A. Dony, T. Baum et al., La conciliation des traitements médicamenteux : logigramme d?une démarche efficiente pour prévenir ou intercepter les erreurs médicamenteuses à l?admission du patient hospitalisé, Le Pharmacien Hospitalier et Clinicien, vol.48, issue.3, pp.153-160, 2013.

H. Autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

D. Sur, Eau disponible pour l'utilisation, 2017.

C. Breuker, O. Abraham, L. Di-trapanie, T. Mura, V. Macioce et al., Patients with diabetes are at high risk of serious medication errors at hospital: Interest of clinical pharmacist intervention to improve healthcare, European Journal of Internal Medicine, vol.38, pp.38-45, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01793426

C. Breuker, V. Macioce, T. Mura, A. Castet-nicolas, Y. Audurier et al., Medication Errors at Hospital Admission and Discharge, Journal of Patient Safety, vol.Publish Ahead of Print, issue.00, p.8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753808

C. Breuker, V. Macioce, T. Mura, Y. Audurier, C. Boegner et al., Medication errors at hospital admission and discharge in Type 1 and 2 diabetes, Diabetic Medicine, vol.34, issue.12, pp.1742-1746, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01743298

A. Penfornis, J. F. Blicklé, B. Fiquet, S. Quéré, and S. Dejager, How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag, vol.10, pp.341-52, 2014.

A. Solini, G. Penno, E. Bonora, C. Fondelli, E. Orsi et al., Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study, Journal of the American Geriatrics Society, vol.61, issue.8, pp.1253-1261, 2013.

T. Min, G. I. Davies, S. Rice, J. Chess, and J. W. Stephens, Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol.12, issue.2, pp.123-127, 2018.

C. F. Christiansen, V. Ehrenstein, U. Heide-jørgensen, S. Skovbo, H. Nørrelund et al., Metformin initiation and renal impairment: a cohort study in Denmark and the UK, BMJ Open, vol.5, issue.9, p.e008531, 2015.

B. Detournay, D. Simon, P. Guillausseau, D. Joly, B. D. Verges et al., Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes, Diabetes & Metabolism, vol.38, issue.2, pp.102-112, 2012.

A. P. Mcgovern, B. Rusholme, S. Jones, J. N. Van-vlymen, H. Liyanage et al., Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study, BMC Nephrology, vol.14, issue.1, pp.198-198, 2013.

S. E. Inzucchi, K. J. Lipska, H. Mayo, C. J. Bailey, and D. K. Mcguire, Metformin in Patients With Type 2 Diabetes and Kidney Disease, JAMA, vol.312, issue.24, p.2668, 2014.

W. R. Lu, J. Defilippi, and A. Braun, Unleash Metformin, Annals of Pharmacotherapy, vol.47, issue.11, pp.1488-1497, 2013.

J. Lalau, F. Kajbaf, Y. Bennis, A. Hurtel-lemaire, F. Belpaire et al., Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4, Diabetes Care, vol.41, issue.3, pp.547-553, 2018.

. Dalem-j-van, M. Brouwers, C. Stehouwer, A. Krings, H. Leufkens et al., Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study, BMJ. 13 juill, vol.354, 2016.

D. Sur,